NCT06844383 - A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

March 31, 2029

Conditions

Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)

Interventions

DRUG

Talazoparib with enzalutamide

Talazoparib (0.5 mg PO QD) and enzalutamide (160 mg PO QD) will be administered in continuous 28-day cycles.

DRUG

Talazoparib

Talazoparib (1 mg PO QD) will be administered in continuous 28-day cycles.

Trial Locations (2)

Memorial Sloan Kettering Cancer Center, New York

Dana Farber Cancer Institute, Boston